775 research outputs found
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
No full textBlood. 2006 Oct 1;108(7):2159-64. Epub 2006 Jun 8.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C,
Marconi M, Leoni P.
Clinica di Ematologia Ospedali Riuniti Ancona, Via Conca, 71, 60020 Ancona, Italy. [email protected]
We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. Thalidomide 100 mg was administered orally at bedtime continuously, dexamethasone 40 mg was administered orally on days 1 to 4 and 9 to 12, and pegylated liposomal doxorubicin 40 mg/m2
was administered intravenously on day 1 over the 28-day cycle. Response was assessed according to the EBMT criteria. Seventeen (34%) patients achieved CR, 7 (14%) nCR, 5 (10%) VGPR, 15 (30%) PR, and 5 (10%) MR, resulting in an ORR of 98%.
Only 1 patient (2%) presented progressive disease. Time to progression (TTP), event-free survival (EFS), and overall survival (OS) projected at 3 years were 60%, 57%, and 74%, respectively, and these parameters were significantly higher in those patients achieving a response of at least VGPR versus those who did not.
Grade 3 and 4 nonhematologic adverse events were constipation (10%), fatigue (6%), tremors (4%), mucositis (4%), and palmar-plantar erythrodysesthesia (2%).
Grade 3 and 4 neutropenia occurred in 12% of patients. Grade 3 and 4 infections and thromboembolic accidents were observed in 22% and 14% of patients, respectively. In the treatment of elderly patients with newly diagnosed multiple
myeloma, ThaDD is a very effective regimen with manageable toxicity
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
No full textMultiple myeloma (MM) is a hematologic malignancy characterized by abnormal growth and/or dysregulation of plasma cells leading to the build-up of malignant plasma cells in the bone marrow and increased production of monoclonal immunoglobulins. Treatment modalities for MM include autologous stem cell transplant (ASCT), chemotherapy with conventional and immunomodulatory agents, radiation therapy and adjunct therapies. Bendamustine is a synthetic chemotherapeutic agent combining the alkylating properties of a mustard group with the activities of a benzimidazole ring, giving it a unique alkylating activity compared with other alkylating agents. Bendamustine has proven activity in both newly diagnosed and relapsed-refractory MM. Bendamustine has also demonstrated activity in MM after relapse from ASCT, and has recently been used successfully as a conditioning regimen for ASCT in combination with melphalan. Bendamustine is generally well tolerated, with the majority of adverse events being due to bone marrow suppression. Extramedullary toxicity is infrequent and usually mil
Infectious complications in adult acute lymphoblastic leukemia (ALL): experience at one single center
No full text
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
No full textPURPOSE OF REVIEW: A working group of six expert physicians convened to assess the spectrum of multiple myeloma relapse presentations, discussed the features that can define the disease as aggressive and not aggressive, and established whether this information could help in selecting treatment together with the characteristics of disease and of patients and type of prior therapy. RECENT FINDINGS: The working group agreed that relapse should be distinguished between biochemical and clinical according to IMWG. Moreover, the expert panel defined "aggressive disease" as a clinical condition that requires therapy able to induce a rapid and as deep as possible response to release symptoms and to avoid impending danger of new events. According to this definition, relapse was considered aggressive if it presents with at least one of the following features: doubling of M protein rate over 2 months, renal insufficiency, hypercalcemia, extramedullary disease, elevated LDH, high plasma cell proliferative index, presence of plasma cells in peripheral blood, or skeletal-related complications. Moreover, the panel agreed that this classification can be useful to choose therapy in first relapse together with other patient, disease, and prior therapy characteristics. So, this item was included in a new therapeutic algorithm. The treatment choice in MM at relapse is wider than in the past with the availability of many new therapeutic regimens leading to increased diversity of approaches and relevant risk of inappropriate treatment decisions. A practical classification of relapses into aggressive or non-aggressive, included in a decisional algorithm on MM management at first relapse, could help to make the appropriate treatment decisions
Solar-driven valorization of glycerol towards production of chemicals and hydrogen
No full textReverse microemulsion-based synthesis was successfully applied to the preparation of nanosized TiO2 particles in anatase and rutile crystalline phases. The resulted nano-oxides were found to have smaller average crystalline size, higher surface area and narrower band gap than commercial TiO2 samples, P25 and DT-51. All the TiO2 materials were used as supports for platinum nanoparticles prepared by incipient wetness impregnation and deposition-precipitation methods. The photo-catalytic activities of these materials were compared in the reaction of glycerol photo-reforming in aqueous media using simulated solar light. The results showed that different crystalline phases of titania have different effects on hydrogen production and selectivity of intermediate products. Anatase was found to be more selective towards glyceraldehyde, while the presence of rutile promoted a more selective reaction towards glycolaldehyde. Rutile also exhibited a higher productivity of hydrogen compared to anatase
La qualità della vita nel paziente psoriasico: esperienza di due anni del centro Psocare della Clinica Dermatologica di Ancona.
No full textA case of hypertrophic lichen ruber planus of the leg complicated by a squamous cell carcinoma
No full text- …
